Eton Pharmaceuticals, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.
|HQ||Palatine, IL, US||Map|
Net income (FY, 2018)
Market capitalization (25-Feb-2021)
Closing stock price (25-Feb-2021)
When was Eton Pharmaceuticals founded?
Eton Pharmaceuticals was founded in 2017.
Who are Eton Pharmaceuticals key executives?
Eton Pharmaceuticals's key executives are Wilson Troutman, Sean Brynjelsen and Norbert Riedel.
How many employees does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 15 employees.
Who are Eton Pharmaceuticals competitors?
Competitors of Eton Pharmaceuticals include MyoKardia, Reata Pharmaceuticals and Biogen.
Where is Eton Pharmaceuticals headquarters?
Eton Pharmaceuticals headquarters is located at 21925 W Field Pkwy #235, Palatine.
Where are Eton Pharmaceuticals offices?
Eton Pharmaceuticals has an office in Palatine.
How many offices does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 1 office.
Receive alerts for 300+ data fields across thousands of companies